VRTX — VERTEX PHARMACEUTICALS INC COM

Ownership history in Exane Asset Management  ·  5 quarters on record

This page tracks every 13F SEC filing in which Exane Asset Management reported a position in VERTEX PHARMACEUTICALS INC COM (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
12.83% (2021 Q1)
Avg. % of fund
4.47%
First filed
2017 Q3
Last filed
2025 Q3
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 100 -206,060 -100.0% 0.02% $46K $391.64
2021 Q2 ADDED 206,160 +50,908 +32.8% 9.43% $41.6M $201.63
2021 Q1 ADDED 155,252 +153,952 +11842.5% 12.83% $33.4M $214.89
2017 Q4 ADDED 1,300 +397 +44.0% 0.06% $195K $149.86
2017 Q3 INITIATED 903 — — 0.03% $137K —
% of Fund (quarterly)    VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Bellevue Group AG 3Y 7Y 5.85% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68%
← Back to Exane Asset Management Holdings